Zalecenia Polskiej Grupy Szpiczakowej dotycz ące rozpoznawania i leczenia szpiczaka plazmocytowego oraz innych dyskrazji plazmocytowych na rok 2016

Publication date: April–June 2016 Source:Acta Haematologica Polonica, Volume 47, Issue 2 Author(s): Anna Dmoszyńska, Adam Walter-Croneck, Barbara Pieńkowska-Grela, Lidia Usnarska-Zubkiewicz, Jan Walewski, Grzegorz Charliński, Wiesław Wiktor Jędrzejczak, Elżbieta Wiater, Ewa Lech-Marańda, Krzysztof Jamroziak, Agnieszka Druzd-Sitek, Dominik Dytfeld, Mieczysław Komarnicki, Tadeusz Robak, Artur Jurczyszyn, Joanna Mańko, Aleksander Skotnicki, Sebastian Giebel, Ryszard Czepko, Janusz Meder, Bogdan Małkowski, Krzysztof Giannopoulos New drugs introduced in recent years for the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. While therapeutic regimens based on bortezomib and thalidomide are recommended to most patients in first-line therapy, lenalidomide represents a cornerstone for treatment of relapsed/refractory myeloma patients. Most patients profit from prolonged treatment composed of consolidation and maintenance or treatment till progression. Beside concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease. In this article, we described also therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias.
Source: Acta Haematologica Polonica - Category: Hematology Source Type: research